Gamida Cell Ltd. (GMDA) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
May 10, 2022 7:00 AM EDT- On track for full BLA submission of omidubicel in the second quarter of 2022 -
- Planning to open sites for enrollment in second quarter of 2022 for Phase 1/2 study of GDA-201 in patients with follicular and diffuse large B-cell lymphomas -
- Presented new preclinical data supporting potential of NAM-enabled, genetically modified NK pipeline cell therapy candidates GDA-301 and GDA-601 -
- Finished first quarter of 2022 with approximately $70 million in cash; sufficient cash to fund the companys... More
